- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03649282
HFNC and NCPAP in Extremely Preterm Infants
August 24, 2018 updated by: Guilherme Sant'Anna, MD
Comparisons of the Dynamic of the Cardiorespiratory System Behavior of Extreme Preterm Infants Receiving Nasal CPAP or High Flow Nasal Cannula During the Immediate Post-extubation Period
To avoid or decrease the rate of complications in preterm infants after disconnection from a mechanical ventilation (extubation), non-invasive respiratory support is routinely used.
While infants are most commonly extubated to nasal continuous positive airway pressure (NCPAP), high flow nasal cannula (HFNC) has emerged as an attractive alternative.
However, research regarding the safety and efficacy of HFNC in the most extreme preterm infants is limited.
Therefore, we hypothesize that immediately after extubation, measures of heart rate and respiratory behavior may be useful to investigate for any differences between HFNC and NCPAP.
Study Overview
Detailed Description
Infants will be studied 30 min after extubation on both modes of support, provided in a random order.
A transition period of 15 min between modes will be given.
For each mode, recordings will be performed for 40 minutes.
Analysis of these recordings will be done off line.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada
- Montreal Children's Hospital
-
Montreal, Quebec, Canada
- Royal Victoria Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Infants with birth weight ≤ 1250 grams
- Infants that have been mechanically ventilated and undergoing their first elective extubation attempt
Exclusion Criteria:
- Major congenital anomalies, neuromuscular disease, hemodynamic instability (use of vasopressors or hypotension).
- Infants reintubated before initiation or during data collection.
- Parental/legal guardian consent not obtained.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HFNC/NCPAP
HFNC will be provided for 45 minutes followed by NCPAP for 45 minutes.
Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
|
HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification.
This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.
NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface.
Nasal prong sizes will be chosen according to manufacturer recommendations.
|
Experimental: NCPAP/HFNC
NCPAP will be provided for 45 minutes followed by HFNC for 45 minutes.
Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
|
HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification.
This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.
NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface.
Nasal prong sizes will be chosen according to manufacturer recommendations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences on Heart Rate Variability in extremely preterm infants receiving HFNC and NCPAP
Time Frame: Immediate post-extubation period
|
Cardiac signals from the electrocardiogram will be continuously measured throughout the recordings.
Analysis of these signals will be performed offline to calculate heart rate variability using linear and nonlinear methods.
|
Immediate post-extubation period
|
Differences on Respiratory Variability in extremely preterm infants receiving HFNC and NCPAP
Time Frame: Immediate post-extubation period
|
Respiratory variability will be calculated by using analysis of respiratory inductive pletysmography signals from the recordings during HFNC and NCPAP.
Desaturation events will also be calculated from these recordings.
|
Immediate post-extubation period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Guilherme M Sant'Anna, MD, PhD, McGill University Health Centre/Research Institute of the McGill University Health Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2013
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
August 21, 2018
First Submitted That Met QC Criteria
August 24, 2018
First Posted (Actual)
August 28, 2018
Study Record Updates
Last Update Posted (Actual)
August 28, 2018
Last Update Submitted That Met QC Criteria
August 24, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-342-PED
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extreme Prematurity
-
University of WashingtonNational Institute of Neurological Disorders and Stroke (NINDS)CompletedExtreme PrematurityUnited States
-
University of Alabama at BirminghamRecruitingPrematurity; ExtremeUnited States
-
Stockholm UniversityKarolinska Institutet; Region Stockholm; Centrum för kompetensutveckling inom... and other collaboratorsActive, not recruiting
-
Level 42 AI, Inc.Georgetown UniversityRecruitingPremature Birth | Prematurity | Premature Lungs | Prematurity; ExtremeUnited States
-
Radboud University Medical CenterUniversity Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Amsterdam... and other collaboratorsCompletedComplications | Extreme Prematurity
-
Assistance Publique - Hôpitaux de ParisRecruitingNewborn | Extreme Prematurity | Pretrm InfantsFrance
-
University of North Carolina, Chapel HillNational Center for Advancing Translational Sciences (NCATS)CompletedParent-Child Relations | Parents | Extreme PrematurityUnited States
-
Christiana Care Health ServicesProvidence Health & ServicesCompletedPregnancy Preterm | Birth, Preterm | Extreme PrematurityUnited States
-
Sharp HealthCareThrasher Research FundTerminatedExtreme Prematurity - Less Than 28 WeeksUnited States, Spain, United Kingdom, Slovenia, Austria, Sweden, Ireland, Poland, Italy, France, Germany, Russian Federation
Clinical Trials on HFNC
-
Columbia UniversityRecruitingAcute Hypoxemic Respiratory FailureUnited States
-
Poitiers University HospitalCompletedImmunosuppression | Acute Respiratory FailureFrance
-
Lahore General HospitalUnknownSARS-CoV Infection | SARS (Severe Acute Respiratory Syndrome)Pakistan
-
Samsung Medical CenterWithdrawnAcute Hypoxemic Respiratory FailureKorea, Republic of
-
The First Affiliated Hospital of Guangzhou Medical...UnknownHigh-flow Nasal Cannula | Non-invasive Positive Pressure Ventilation | Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseChina
-
Poitiers University HospitalCompletedAcute Respiratory Failure Requiring ReintubationFrance
-
Southeast University, ChinaThe Second Hospital of Nanjing Medical University; Second Affiliated Hospital... and other collaboratorsUnknownRespiratory Failure
-
Asan Medical CenterMinistry of Trade, Industry & Energy, Republic of KoreaCompletedHypoxia | Ventilation | High Flow Nasal Cannula | Oxygen Therapy
-
OhioHealthTerminatedVentilatory FailureUnited States
-
Rush University Medical CenterCompletedHypoxemiaUnited States